22 completed, 4 recruiting, 3 terminated, 1 active not recruiting. 31 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 31 | Completed 22, Recruiting 4, Terminated 3, Active not recruiting 1, Not yet recruiting 1 |
| Phase 3 | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
Follow Albuminuria: new trials by email Literature Review of Albuminuria trials Research Report on Albuminuria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mesenchymal Stem Cell Exosomes Alone or Combined With HUVEC Exosomes in Non-Dialysis Chronic Kidney Disease Human Wharton's jelly mesenchymal stem cell (HWJ-MSC) exosomes, Human umbilical vein endothelial cell (HUVEC) exosomes, Placebo (0.9% sodium chloride) - Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4 | Phase 1 / Phase 2 | Completed | Nurhasan Agung Prabowo | 34 | 2026-07-01 | 2026-11-06 |
| Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin Empagliflozin (oral) - Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Albuminuria | Phase 2 | Recruiting | University of Illinois at Chicago | 20 | 2026-04-08 | 2026-05-19 |
| A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease Guominkang Granules, Standard Antihypertensive, Antidiabetic, and Lipid-Lowering Regimen - Diabetic Kidney Disease (DKD), Type 2 Diabetes | Phase 2 | Active not recruiting | Beijing University of Chinese Medicine | 15 | 2025-10-20 | 2026-11-02 |
| Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia Sotagliflozin, Placebo - Nephropathy, Diabetic Nephropathies | Phase 2 | Not yet recruiting | Steno Diabetes Center Copenhagen | 69 | 2025-02-01 | 2025-01-27 |
| The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease dapagliflozin, Other anti-diabetic drug or no anti-diabetic drug, empagliflozin - Acute Kidney Injury | Phase 2 | Recruiting | National Taiwan University Hospital | 264 | 2024-11-21 | 2026-01-02 |
| Effect Camostat for Kidney Protection in Chronic Kidney Disease Camostat Mesylate - Chronic Kidney Disease(CKD) | Phase 2 | Recruiting | Odense University Hospital | 40 | 2024-11-21 | 2025-01-27 |
| Safety and Efficacy of the Combination Therapy of Fucoidan / Fucoxanthin / L-carnitine in Patients With Diabetic Nephropathy. Oligo-fucoidan, Fucoxanthin, L-carnitine Formula, Zinc yeast (FFL) - Diabetic Kidney Disease (DKD) | Phase 2 | Completed | Taipei Medical University WanFang Hospital | 63 | 2024-11-06 | 2026-09-04 |
| The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study Finerenone Oral Tablet, Placebo - Kidney Transplant; Complications | Phase 2 | Recruiting | University of North Carolina, Chapel Hill | 100 | 2024-04-23 | 2026-04-14 |
| Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD - Chronic Kidney Disease | Phase 2 | Completed | Mineralys Therapeutics Inc. | 60 | 2023-12-14 | 2026-06-03 |
| Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria Zibotentan, Dapagliflozin, Placebo - Chronic Kidney Diseases | Phase 2 | Completed | University Medical Center Groningen | 42 | 2022-10-06 | 2025-04-30 |
| TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertension Dapagliflozin 10Mg Tab, Placebo - Albuminuria | Phase 2 | Terminated | University Medical Center Groningen | 9 | 2022-02-03 | 2024-04-17 |
| SER150 vs Placebo in Diabetic Kidney Disease SER150, Placebo - Diabetic Kidney Disease | Phase 2 / Phase 3 | Completed | Serodus AS | 20 | 2021-08-18 | 2024-06-21 |
| Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria Lisinopril, Placebo Oral Tablet - HIV/AIDS, Albuminuria | Phase 2 | Terminated | Vanderbilt University Medical Center | 66 | 2021-04-01 | 2025-06-26 |
| Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease Crizanlizuamb, Standard of Care - Sickle Cell Disease (SCD) | Phase 2 | Completed | Novartis Pharmaceuticals | 58 | 2019-12-10 | 2024-10-09 |
| SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial) Hydroxycarbamide, Placebo Oral Tablet - Sickle Cell Disease | Phase 2 | Completed | Theravia | 86 | 2019-05-28 | 2025-05-14 |
| Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria Verinurad 9 mg+Febuxostat 80 mg, Placebo - Hyperuricemia, Albuminuria | Phase 2 | Completed | AstraZeneca | 60 | 2017-05-18 | 2020-01-10 |
| Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency Evogliptin, Linagliptin - Type2 Diabetes Mellitus, Albuminuria | Phase 2 | Completed | Samsung Medical Center | 209 | 2017-03-16 | 2019-09-23 |
| A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD Dapagliflozin 10 mg, Saxagliptin 2.5 mg, Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg - Type 2 Diabetes Mellitus, CKD and Albuminuria | Phase 2 / Phase 3 | Completed | AstraZeneca | 459 | 2015-09-21 | 2019-08-21 |
| Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease Spironolactone, Amiloride - Chronic Kidney Disease, Albuminuria | Phase 2 | Completed | University of Alabama at Birmingham | 21 | 2015-03-01 | 2022-12-21 |
| Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria GKT137831, Placebo - Type 2 Diabetes Mellitus With Diabetic Nephropathy | Phase 2 | Completed | Calliditas Therapeutics AB | 136 | 2013-10-01 | 2025-02-28 |
Showing 20 of 31. Sign in to see all of them.
Diabetic Nephropathies (12) · Diabetes Mellitus, Type 2 (10) · Renal Insufficiency, Chronic (8) · Anemia, Sickle Cell (4) · Kidney Diseases (4) · Proteinuria (3) · Diabetes Mellitus (2) · Hypertension (2) · Acquired Immunodeficiency Syndrome (1) · Acute Kidney Injury (1) · Diabetes Mellitus, Type 1 (1) · Genetic Predisposition to Disease (1) · Heart Failure (1) · Hyperuricemia (1)
Female Urogenital Diseases (31) · Female Urogenital Diseases and Pregnancy Complications (31) · Male Urogenital Diseases (31) · Pathological Conditions, Signs and Symptoms (31) · Signs and Symptoms (31) · Urination Disorders (31) · Urogenital Diseases (31) · Urologic Diseases (31) · Urological Manifestations (31) · Proteinuria (28) · Endocrine System Diseases (18) · Kidney Diseases (18) · Diabetes Mellitus (16) · Diabetes Complications (12) · Glucose Metabolism Disorders (12)
dapagliflozin (4) · Sugars (2) · empagliflozin (2) · (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol (1) · 4-(3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl)piperazin-2-one (1) · Amiloride (1) · Ascorbic Acid (1) · Atorvastatin (1) · Canagliflozin (1) · Cholecalciferol (1) · Eplerenone (1) · Febuxostat (1) · Fosinopril (1) · Hydroxyurea (1) · Hypoglycemic Agents (1)
AstraZeneca (2) · University Medical Center Groningen (2) · University of North Carolina, Chapel Hill (2) · Ardelyx (1) · Aziende Chimiche Riunite Angelini Francesco S.p.A (1) · Beijing University of Chinese Medicine (1) · Calliditas Therapeutics AB (1) · InVasc Therapeutics, Inc. (1) · Mineralys Therapeutics Inc. (1) · National Taiwan University Hospital (1) · Novartis Pharmaceuticals (1) · Nurhasan Agung Prabowo (1) · Odense University Hospital (1) · Pfizer (1) · Radboud University Medical Center (1)
United States (17) · Australia (4) · Canada (4) · Netherlands (4) · Denmark (3) · Germany (3) · Poland (3) · South Korea (3) · Spain (3) · Taiwan (3) · United Kingdom (3) · Czechia (2) · France (2) · Italy (2) · Romania (2)
Amy Mottl, MD, MPH (1) · C. William Wester, MD, MPH (1) · Claus Bistrup, MD, Professor (1) · Giuseppe Remuzzi, PhD (1) · Hiddo J Lambers Heerspink, PhD, PharmD (1) · Ian H de Boer, MD, MS (1) · Jacob Deinum, MD (1) · Jae Hyeon Kim, MD PhD (1) · John Burkart, MD (1) · Kai Riecke, MD (1) · Kenneth I Ataga, MBBS (1) · Muktar H. Aliyu, MD, DrPH (1) · Pablo Bartolucci, Pr (1)
PMID 41805697, PMID 30957581, PMID 30992195, PMID 33107592, PMID 33130235, PMID 33184642, PMID 34383954, PMID 37254256, PMID 38017482, PMID 38770818, PMID 39382091, PMID 40193211, PMID 40569673
1KL2RR025015-01 (1), 2018 (1), 2023 (1), P30DK017047 (1), R01HL111659 (1), R21AT002367 (1), U01DK112271 (1)